AstraZeneca Plc is testing one of its diabetes drugs as a treatment for COVID-19.
The trial of 900 hospitalized patients, called DARE-19, will test Farxiga against a placebo with results expected by December.
"While we don't fully understand the mechanisms of how these medications protect the heart and kidneys, we know that they do," Dr. Kosiborod said. "We know that they do that in patient populations that have cardiometabolic disease--exactly the same patient population that are at such high risk in the setting of COVID-19."
Read the full Reuters article: AstraZeneca tests diabetes drug for COVID-19